ALB and kidney disorder: In recent decades, some clinical [8, 9], pathological [10, 11], and genetic [12, 13] parameters have been identified as biomarkers for predicting the prognosis of IMN, and the Kidney Disease Improving Global Outcomes (KDIGO) 2021 clinical practice guideline have taken 24 h urinary protein (UTP), estimate glomerular filtration rate(eGFR), serum anti-phospholipase A2 receptor antibody (sPLA2R-Ab), serum albumin (ALB) and others as indicators that may be used to divide patients into categories of low, moderate, high, and very high risk of progressive loss of kidney function [14].